| 3.08 0.84 (37.5%) | 08-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.64 |
1-year : | 4.25 |
| Resists | First : | 3.11 |
Second : | 3.64 |
| Pivot price | 2.1 |
|||
| Supports | First : | 2.36 |
Second : | 1.9 |
| MAs | MA(5) : | 2.26 |
MA(20) : | 2.1 |
| MA(100) : | 2 |
MA(250) : | 1.85 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 79.2 |
D(3) : | 57.4 |
| RSI | RSI(14): 80.4 |
|||
| 52-week | High : | 3.11 | Low : | 1.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ OABI ] has closed Bollinger Bands are 83.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.27 - 2.28 | 2.28 - 2.29 |
| Low: | 2.02 - 2.03 | 2.03 - 2.04 |
| Close: | 2.22 - 2.24 | 2.24 - 2.26 |
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Fri, 07 Aug 2026
OmniAb, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-08-07 - Seeking Alpha
Fri, 07 Aug 2026
OmniAb Q2 Earnings Call Highlights - tradingview.com
Fri, 07 Aug 2026
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... - Yahoo Finance
Thu, 06 Aug 2026
OmniAb (NASDAQ:OABI) Beats Q2 Estimates and Raises Full-Year Guidance - ChartMill
Thu, 06 Aug 2026
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Thu, 06 Aug 2026
OmniAb (NASDAQ: OABI) grows partner base and cuts cash burn in 2026 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 145 (M) |
| Shares Float | 114 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 51 (%) |
| Shares Short | 5,880 (K) |
| Shares Short P.Month | 4,700 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.8 |
| Profit Margin | -187.6 % |
| Operating Margin | -54.3 % |
| Return on Assets (ttm) | -11.4 % |
| Return on Equity (ttm) | -20.3 % |
| Qtrly Rev. Growth | 247.3 % |
| Gross Profit (p.s.) | 0.19 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -0.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -6.7 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 15.42 |
| Price to Cash Flow | -17.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|